Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 12/20 | 0.74 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.70 |
| ▸ | RPS6KA2 | Q15349 | 6/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13143400 | 0.86 | MAPKAPK2 (0.65) | MAPKAPK2RPS6KA3RPS6KA2 | |
| SCHEMBL13143368 | 0.86 | MAPKAPK2 (0.72) | MAPKAPK2RPS6KA3RPS6KA2 | |
| SCHEMBL13143471 | 0.83 | MAPKAPK2 (0.66) | MAPKAPK2RPS6KA3RPS6KA2 | |
| SCHEMBL12595353 | 0.83 | RPS6KA3 (1.00) | MAPKAPK2RPS6KA3RPS6KA2 | |
| SCHEMBL13143309 | 0.81 | RPS6KA2 (0.70) | MAPKAPK2RPS6KA3RPS6KA2 | |
| SCHEMBL13143340 | 0.81 | RPS6KA2 (0.74) | RPS6KA3RPS6KA2 | |
| SCHEMBL13143347 | 0.81 | RPS6KA2 (0.80) | RPS6KA3RPS6KA2 | |
| SCHEMBL3090074 | 0.81 | RPS6KA2 (0.73) | RPS6KA3RPS6KA2 | |
| SCHEMBL3091036 | 0.80 | RPS6KA2 (0.72) | RPS6KA3RPS6KA2 | |
| SCHEMBL5905631 | 0.80 | MAPKAPK2 (0.64) | MAPKAPK2RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790712-B2 | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790712-B2 | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790712-B2 | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885RPS6KA3 302/4885RPS6KA2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.